Novel compound VB-037 inhibits Aβ aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease

Ya Jen Chiu, Yu Hsuan Hsieh, Te Hsien Lin, Guan Chiun Lee, Hsiu Mei Hsieh-Li, Ying Chieh Sun, Chiung Mei Chen, Kuo Hsuan Chang, Guey Jen Lee-Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The pathogenesis of Alzheimer's disease (AD) is involved in the aggregation of misfolded amyloid β (Aβ), which upregulates the activity of acetylcholinesterase (AChE), increases the production of reactive oxygen species (ROS), enhances neuroinflammation, and eventually leads to neuronal death. Therefore, compounds targeting these mechanisms may be candidates for multitarget drugs in AD treatment. We found that two quinoline derivatives, VB-030 and VB-037, markedly reduced Aβ aggregation and ROS levels in the thioflavin T biochemical assay and Tet-On Aβ-green fluorescent protein (GFP) 293 AD cell model. These compounds further improved neurite outgrowth, reduced AChE activity and upregulated the molecular chaperone heat shock protein family B [small] member 1 (HSP27), whereas knockdown of HSP27 counteracted the compounds’ neuroprotective effects on the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Furthermore, VB-037 attenuated lipopolysaccharide (LPS)/interferon (IFN)-γ-induced activation of BV-2 microglial cells. In addition, VB-037 demonstrated its potential to diminish LPS/IFN-γ-induced upregulation of caspase 1 activity, expression of interleukin (IL)-1β and active phosphorylation of mitogen-activated protein kinase 14 (P38), mitogen-activated protein kinase 8 (JNK), and Jun proto-oncogene, AP-1 transcription factor subunit (JUN) signalings, as well as improve cell viability in the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Our findings strongly indicate the potential of VB-037 for modifying AD progression by targeting multiple mechanisms, thereby offering a new drug development avenue for AD treatment.

Original languageEnglish
Pages (from-to)175-186
Number of pages12
JournalNeurochemistry International
Volume125
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

Alzheimer Disease
Inflammation
Green Fluorescent Proteins
p38 Mitogen-Activated Protein Kinases
Acetylcholinesterase
Interferons
Lipopolysaccharides
Reactive Oxygen Species
Mitogen-Activated Protein Kinase 14
Up-Regulation
Mitogen-Activated Protein Kinase 8
jun Genes
Caspase 1
Molecular Chaperones
Transcription Factor AP-1
Neuroprotective Agents
Heat-Shock Proteins
Neuronal Outgrowth
Interleukin-1
Amyloid

Keywords

  • Alzheimer's disease
  • Aβ aggregation
  • P38/JNK signaling pathways
  • Synthetic quinoline derivatives
  • Therapeutics

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

@article{31dede69a7ed47d8b7d6dd4c1a8faf6e,
title = "Novel compound VB-037 inhibits Aβ aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease",
abstract = "The pathogenesis of Alzheimer's disease (AD) is involved in the aggregation of misfolded amyloid β (Aβ), which upregulates the activity of acetylcholinesterase (AChE), increases the production of reactive oxygen species (ROS), enhances neuroinflammation, and eventually leads to neuronal death. Therefore, compounds targeting these mechanisms may be candidates for multitarget drugs in AD treatment. We found that two quinoline derivatives, VB-030 and VB-037, markedly reduced Aβ aggregation and ROS levels in the thioflavin T biochemical assay and Tet-On Aβ-green fluorescent protein (GFP) 293 AD cell model. These compounds further improved neurite outgrowth, reduced AChE activity and upregulated the molecular chaperone heat shock protein family B [small] member 1 (HSP27), whereas knockdown of HSP27 counteracted the compounds’ neuroprotective effects on the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Furthermore, VB-037 attenuated lipopolysaccharide (LPS)/interferon (IFN)-γ-induced activation of BV-2 microglial cells. In addition, VB-037 demonstrated its potential to diminish LPS/IFN-γ-induced upregulation of caspase 1 activity, expression of interleukin (IL)-1β and active phosphorylation of mitogen-activated protein kinase 14 (P38), mitogen-activated protein kinase 8 (JNK), and Jun proto-oncogene, AP-1 transcription factor subunit (JUN) signalings, as well as improve cell viability in the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Our findings strongly indicate the potential of VB-037 for modifying AD progression by targeting multiple mechanisms, thereby offering a new drug development avenue for AD treatment.",
keywords = "Alzheimer's disease, Aβ aggregation, P38/JNK signaling pathways, Synthetic quinoline derivatives, Therapeutics",
author = "Chiu, {Ya Jen} and Hsieh, {Yu Hsuan} and Lin, {Te Hsien} and Lee, {Guan Chiun} and Hsieh-Li, {Hsiu Mei} and Sun, {Ying Chieh} and Chen, {Chiung Mei} and Chang, {Kuo Hsuan} and Lee-Chen, {Guey Jen}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.neuint.2019.01.021",
language = "English",
volume = "125",
pages = "175--186",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Novel compound VB-037 inhibits Aβ aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease

AU - Chiu, Ya Jen

AU - Hsieh, Yu Hsuan

AU - Lin, Te Hsien

AU - Lee, Guan Chiun

AU - Hsieh-Li, Hsiu Mei

AU - Sun, Ying Chieh

AU - Chen, Chiung Mei

AU - Chang, Kuo Hsuan

AU - Lee-Chen, Guey Jen

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The pathogenesis of Alzheimer's disease (AD) is involved in the aggregation of misfolded amyloid β (Aβ), which upregulates the activity of acetylcholinesterase (AChE), increases the production of reactive oxygen species (ROS), enhances neuroinflammation, and eventually leads to neuronal death. Therefore, compounds targeting these mechanisms may be candidates for multitarget drugs in AD treatment. We found that two quinoline derivatives, VB-030 and VB-037, markedly reduced Aβ aggregation and ROS levels in the thioflavin T biochemical assay and Tet-On Aβ-green fluorescent protein (GFP) 293 AD cell model. These compounds further improved neurite outgrowth, reduced AChE activity and upregulated the molecular chaperone heat shock protein family B [small] member 1 (HSP27), whereas knockdown of HSP27 counteracted the compounds’ neuroprotective effects on the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Furthermore, VB-037 attenuated lipopolysaccharide (LPS)/interferon (IFN)-γ-induced activation of BV-2 microglial cells. In addition, VB-037 demonstrated its potential to diminish LPS/IFN-γ-induced upregulation of caspase 1 activity, expression of interleukin (IL)-1β and active phosphorylation of mitogen-activated protein kinase 14 (P38), mitogen-activated protein kinase 8 (JNK), and Jun proto-oncogene, AP-1 transcription factor subunit (JUN) signalings, as well as improve cell viability in the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Our findings strongly indicate the potential of VB-037 for modifying AD progression by targeting multiple mechanisms, thereby offering a new drug development avenue for AD treatment.

AB - The pathogenesis of Alzheimer's disease (AD) is involved in the aggregation of misfolded amyloid β (Aβ), which upregulates the activity of acetylcholinesterase (AChE), increases the production of reactive oxygen species (ROS), enhances neuroinflammation, and eventually leads to neuronal death. Therefore, compounds targeting these mechanisms may be candidates for multitarget drugs in AD treatment. We found that two quinoline derivatives, VB-030 and VB-037, markedly reduced Aβ aggregation and ROS levels in the thioflavin T biochemical assay and Tet-On Aβ-green fluorescent protein (GFP) 293 AD cell model. These compounds further improved neurite outgrowth, reduced AChE activity and upregulated the molecular chaperone heat shock protein family B [small] member 1 (HSP27), whereas knockdown of HSP27 counteracted the compounds’ neuroprotective effects on the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Furthermore, VB-037 attenuated lipopolysaccharide (LPS)/interferon (IFN)-γ-induced activation of BV-2 microglial cells. In addition, VB-037 demonstrated its potential to diminish LPS/IFN-γ-induced upregulation of caspase 1 activity, expression of interleukin (IL)-1β and active phosphorylation of mitogen-activated protein kinase 14 (P38), mitogen-activated protein kinase 8 (JNK), and Jun proto-oncogene, AP-1 transcription factor subunit (JUN) signalings, as well as improve cell viability in the Tet-On Aβ-GFP SH-SY5Y AD neuronal model. Our findings strongly indicate the potential of VB-037 for modifying AD progression by targeting multiple mechanisms, thereby offering a new drug development avenue for AD treatment.

KW - Alzheimer's disease

KW - Aβ aggregation

KW - P38/JNK signaling pathways

KW - Synthetic quinoline derivatives

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85060932838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060932838&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2019.01.021

DO - 10.1016/j.neuint.2019.01.021

M3 - Article

C2 - 30707915

AN - SCOPUS:85060932838

VL - 125

SP - 175

EP - 186

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

ER -